M Marc PEREZ

Rhumatologue

📍 PARIS (75)SalariéRPPS 10000303072

Publications actives

25 publications sur 5 ans

📊 Reconnaissance scientifique : 16/100📝 34 articles publiés🇫🇷 Publications académiques françaises (8)

✨ Profil synthétique

IA · 19/05/2026

Le Dr Marc PEREZ est un rhumatologue salarié à Paris, avec une activité de recherche centrée sur les infections virales respiratoires et le COVID-19. Il a publié 34 articles et possède un h-index de 16 selon OpenAlex. Ses publications sur PubMed couvrent des sujets tels que la pharmacovigilance, l'arthrite juvénile et l'utilisation de l'intelligence artificielle en rhumatologie.

Expertises présumées

Pharmacovigilance
Arthrite juvénile
Essai clinique
Intelligence artificielle en rhumatologie
Pédiatrie rhumatologique
Infections virales respiratoires
Recherche sur le COVID-19

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Articles de presse (6)

Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).

Vous êtes nombreux à miser sur cette boisson chaude quand vous êtes malade, or un médecin alerte : "Elle n'a aucun intérêt et elle diminue l'immunité !" - Top Santé

📰 Top Santé · 21/12/2025

<a href="https://news.google.com/rss/articles/CBMiowJBVV95cUxPbjV0d21CR2ZrRHNPc05aUlRDT1BaandIMGQ3ZnlTdWFzanRuWkxxM3AtdElweDZRMFhiOWlocFBWR0FzRWVOTFhVZnpndmJSWktwNkJNSVo3NmRzSFdCWFdxTEtPd0xDMmJOX3oyNlNGZjU4eXhuQzUtd0hPcGJLaEI5YjVDcnlLeERHNlpfSUtXbXU2M3hhRzlvX1pVYTBOQ0d3Mmlzb01qMmx4S1BkRVYxMzhsQXVxaU

"Le gainage est-il bon pour le dos ?" Un médecin du sport répond et partage sa routine idéale - Femme Actuelle

📰 Femme Actuelle · 18/10/2025

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxOU3lsQWF4ejJQUGgtSC1Xb3h5Tk5MOEJBWFl1dTQxS181U0ZDRFBycHI2VkFzRy12dTZJenFyVEFOR0R5V3FUdVpDbEF4eVJwTzBTZnZaNF80TC00OVJVRXZNMzF4ZlVKQ2lKanpnV2YtcHVsVmZadkNvaWhTRDY5MHVDNnRmYlFlckZoTWd3VU1CSWxuZjZOZVlwTkw5R21RTGZ6MURUWW9CQ29uN1ZDcHVpLXpJcmNRQ2

J’ai testé 10 jours de "cure énergie" avant l'hiver : voici les résultats incroyables sur mon corps - Top Santé

📰 Top Santé · 08/10/2024

<a href="https://news.google.com/rss/articles/CBMimAJBVV95cUxPX1NudWx4a215NGRYSUROQ2FEQmtMSG03dFl1U0tmOE5PZEMyMkpObFVYN3liUl9Fcm11a3N2MDJqa2lkZ19ONUpQSUl4REIwSjExTnBZOS1makFpM1NSenhvaUdtM2lUZFdkN2RDV05FMktUZjhBQkNPVjVjRlBwTzVYYlRnYmhMT1FyOEcwVS0tZkhEeVp2ZHB1bWRjRy1rODZvb3BCNkdnaFFuRmFKNmRveXVtNHU2QT

Coupe du monde féminine de football : comment éviter les blessures, récupérer et reprendre le sport - ici.fr

📰 ici.fr · 28/06/2019

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxQQ3RKdVVxSVVNWVVXcXc5ckFSSW9EN1I3ckdFMkxHWEFnbHlZbjVmVW9idVVwdnoyOUJUV1ROTVR1dWJKTlhCa1EyN3NRcWdzMlctOGZHMWZfamNnZWlEX25UazZIQkQ1WEtaM0FjYlZUSGN4NTVoeTRrQThkWkJ4aU1ETnJZMV9ZbktDemw3MGN5NXFtZzNuTEZWaFF1bVozbExwUERkN29MYVhqN2VIdVNJai1wSkZoSX

Les guitaristes Marc et Joshua Perez sortent un CD - ladepeche.fr

📰 ladepeche.fr · 30/01/2016

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNaEs2NTg1aFFnM0hvdm53ZWUyLTFnYjByREwzb3RfXzNQTDJUYnhpUVRyZ05VTFd6RnYwLVRFWlFtUkpIM3BSTWt1SzhxYkMyelV4RVZvaGNrMWxSbTV4VE82VzJEQVg1VzJhRVNtZ1ZtYkZORElQZUhZYmpYa2dGRW8zcVU4aDRGdUM1NkEyMW1hdWk0QXJFUWg5VzJlVUN3cUdRdk1YazFUS1U?oc=5" target="_bla

Retraite pour Dr Michel Morin après plus de 30 ans à l'hôpital de Flers - Ouest-France

📰 Ouest-France · 29/01/2010

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPRURwMkJwaUFQZklGQ3ZRd0xZN2JScUFuakZVc2E3Mmpycl9RMDhuWDltTTlsM1prQy1wU0ltTzl3N2tWMkE0ZVJRbG5jS2hCNXFEcDB6MjJPUWlfTnhFc1E5ajBIZzViZTltQWNWLWw3OUxET3F6OTM4MG5obWZJXzkxOGdWdUZUVXRvN2UzY3RtLVNVRnFwczA4aGdHRzhKZkNMVVpQOUpnUVl0aEZNN2lPa3pNVUtnSV

Top publications · les plus citées

Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults

The New England journal of medicine · 2023

📚 358 citations🎯 RCR 41.63Top 0% NIH🩺 Clinique🔓 Open Access

Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial

Obstetrics and gynecology · 2025

📚 62 citations🎯 RCR 26.09🩺 Clinique🔓 Open Access

Lire l'abstract Crossref ↓

OBJECTIVE: To evaluate descriptive efficacy data, exploratory immunogenicity data, and safety follow-up through study completion from the global, phase 3 MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal vaccination trial of bivalent respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVpreF). METHODS: MATISSE was a phase 3, randomized, double-blinded, placebo-controlled trial. Healthy pregnant participants aged 49 years or younger at 24–36 weeks of gestation were randomized (1:1) to receive a single RSVpreF 120 micrograms or placebo dose. Primary efficacy endpoints included newborn and infant severe RSV-associated medically attended lower respiratory tract illness within 180 days after birth. The RSV-A and RSV-B serum neutralizing antibody titers were determined in a subset of pregnant participants and their newborns. RESULTS: In this final analysis, 7,420 pregnant participants were randomized, and 7,307 children were born (RSVpreF n=3,660, placebo n=3,647). Vaccine efficacy, defined as protection against newborn and infant severe RSV-associated medically attended lower respiratory tract illness, was 82.4% (95% CI, 57.5–93.9) and 70.0% (95% CI, 50.6–82.5) within 90 and 180 days of birth, respectively. The RSVpreF induced robust immune responses in pregnant participants and resulted in highly efficient transfer of maternal antibodies to their newborns across subgroups (by gestational age at delivery and at vaccination, number of days from vaccination to delivery, country, maternal age). Final RSVpreF safety results in pregnant and newborn and infant participants were consistent with the primary analysis with no new safety concerns identified. CONCLUSION: This final analysis of MATISSE trial data confirms the primary analysis conclusions: Maternal vaccination with RSVpreF has a favorable safety profile in both pregnant and newborn and infant participants and demonstrates efficacy against RSV-associated lower respiratory tract illness in infants through age 6 months. The RSVpreF induces robust immune responses in pregnant individuals, with corresponding high RSV-neutralizing titers in their newborns. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT04424316.

Best Practice Recommendations for the Diagnosis and Management of Children With Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 (PIMS-TS; Multisystem Inflammatory Syndrome in Children, MIS-C) in Switzerland

Frontiers in pediatrics · 2021

📚 55 citations🎯 RCR 3.61Top 12% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Background: Following the spread of the coronavirus disease 2019 (COVID-19) pandemic a new disease entity emerged, defined as Pediatric Inflammatory Multisystem Syndrome temporally associated with COVID-19 (PIMS-TS), or Multisystem Inflammatory Syndrome in Children (MIS-C). In the absence of trials, evidence for treatment remains scarce.Purpose: To develop best practice recommendations for the diagnosis and treatment of children with PIMS-TS in Switzerland. It is acknowledged that the field is changing rapidly, and regular revisions in the coming months are pre-planned as evidence is increasing.Methods: Consensus guidelines for best practice were established by a multidisciplinary group of Swiss pediatric clinicians with expertise in intensive care, immunology/rheumatology, infectious diseases, hematology, and cardiology. Subsequent to literature review, four working groups established draft recommendations which were subsequently adapted in a modified Delphi process. Recommendations had to reach &gt;80% agreement for acceptance.Results: The group achieved agreement on 26 recommendations, which specify diagnostic approaches and interventions across anti-inflammatory, anti-infectious, and support therapies, and follow-up for children with suspected PIMS-TS. A management algorithm was derived to guide treatment depending on the phenotype of presentation, categorized into PIMS-TS with (a) shock, (b) Kawasaki-disease like, and (c) undifferentiated inflammatory presentation.Conclusion: Available literature on PIMS-TS is limited to retrospective or prospective observational studies. Informed by these cohort studies and indirect evidence from other inflammatory conditions in children and adults, as well as guidelines from international health authorities, the Swiss PIMS-TS recommendations represent best practice guidelines based on currently available knowledge to standardize treatment of children with suspected PIMS-TS. Given the absence of high-grade evidence, regular updates of the recommendations will be warranted, and participation of patients in trials should be encouraged.

Cookies & analyse de trafic

M Marc PEREZ

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Articles de presse (6)

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal33

Pharmacovigilance4

Arthrite juvénile2

Essai clinique2

IA en rhumatologie2

Pédiatrie2

Case report / série1

Corticothérapie1

Gériatrie1

IRM ostéo-articulaire1

Lupus1

Revue / méta-analyse1

Revue générale1

Datasets & protocoles partagés

Partager cette fiche